FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Raises Opinion On Shares Of Gildan Activewear To Buy From Hold

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We maintain our 12-month price target of CAD98, based on 16.0x our 2026 EPS estimate and above the company's five-year average forward P/E multiple of 12.9x, reflecting our view that the company deserves an above-peer multiple. We view the recent acquisition of HanesBrands as positive and believe the company will improve Hanes' operating efficiency while capitalizing on significant synergies. GIL reported Q1 2026 results that reflect the significant impact of its HanesBrands acquisition, with revenues increasing 64% to $1.17B, $18M above estimates, while facing substantial integration-related charges. Adjusted EPS from continuing operations declined to $0.43 from $0.59, $0.08 above consensus estimates, reflecting higher share count from the acquisition and ongoing integration expenses. We now view shares more positively after a 20% decline from its 52-week high just a few months ago. Shares currently trade at 13.5x the midpoint of the company's full-year EPS guidance.

Related Articles

Research

Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.

$VRTX
Asia

ALS Flags Unauthorized Access to Its IT Systems

ALS (ASX:ALQ) reported a cyber incident involving unauthorized third-party access to some of its information technology (IT) systems, temporarily disrupting parts of its operations, according to a Tuesday Australian bourse filing.The company, with support from external cybersecurity specialists, has implemented containment measures in line with incident response procedures, restoring most operations while continuing targeted remediation in affected areas, per the filing.The company has informed the Australian Cyber Security Center and is investigating the full extent of the breach and its potential data impact, the filing added.

$ASX:ALQ
Asia

Dexus Secures JV With Boral for Major Ravenhall Logistics Precinct in Melbourne

Dexus (ASX:DXS) has entered a joint venture (JV) with Boral (ASX:BLD) to develop a large-scale logistics precinct in Ravenhall, Melbourne's western corridor, spanning 630 hectares and targeting up to 2.5 million square meters of lettable space, subject to rezoning and regulatory approvals, according to a Tuesday Australian bourse filing.The JV structure gives the company and other capital partners a combined 50% stake, while Boral retains the remaining 50%, with the project developed in staged superlots and supported by substantial third-party capital to enhance capital efficiency, per the filing.The company will oversee rezoning, development, and management, with limited short-term financial impact, while management fees will begin as each stage of investment is completed, the filing added.

$ASX:BLD$ASX:DXS